Regulation of the complement cascade by soluble complement receptor type 1: protective effect in experimental liver ischemia and reperfusion
RE Chávez-Cartaya, GP DeSola, L Wright… - …, 1995 - journals.lww.com
RE Chávez-Cartaya, GP DeSola, L Wright, NV Jamieson, DJG White
Transplantation, 1995•journals.lww.comThe complement cascade was inactivated in a model of rat liver ischemia with the purpose
of studying the role of complement in tissue injury after ischemia and reperfusion. Soluble
human complement receptor type 1 (sCRl) was administered either in a single dose of 25
mg/kg or in 2 doses of 50 mg/kg iv over 24 hr after vascular occlusion. Sham-operated rats,
nontreated rats submitted to liver ischemia, and rats pretreated with cobra venom factor and
submitted to liver ischemia were used as controls.
of studying the role of complement in tissue injury after ischemia and reperfusion. Soluble
human complement receptor type 1 (sCRl) was administered either in a single dose of 25
mg/kg or in 2 doses of 50 mg/kg iv over 24 hr after vascular occlusion. Sham-operated rats,
nontreated rats submitted to liver ischemia, and rats pretreated with cobra venom factor and
submitted to liver ischemia were used as controls.
Abstract
The complement cascade was inactivated in a model of rat liver ischemia with the purpose of studying the role of complement in tissue injury after ischemia and reperfusion. Soluble human complement receptor type 1 (sCRl) was administered either in a single dose of 25 mg/kg or in 2 doses of 50 mg/kg iv over 24 hr after vascular occlusion. Sham-operated rats, nontreated rats submitted to liver ischemia, and rats pretreated with cobra venom factor and submitted to liver ischemia were used as controls.
Lippincott Williams & Wilkins